These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30472288)

  • 1. Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen.
    Wilkes S; van Berlo I; Ten Oever J; Jansman F; Ter Heine R
    Int J Antimicrob Agents; 2019 Mar; 53(3):310-317. PubMed ID: 30472288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High unbound flucloxacillin fraction in critically ill patients.
    Wallenburg E; Ter Heine R; de Lange DW; van Leeuwen H; Schouten JA; Ten Oever J; Kolwijck E; Burger DM; Pickkers P; Gieling EM; de Maat MM; Frenzel T; Brüggemann RJ
    J Antimicrob Chemother; 2021 Nov; 76(12):3220-3228. PubMed ID: 34463730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total flucloxacillin plasma concentrations poorly reflect unbound concentrations in hospitalized patients with Staphylococcus aureus bacteraemia.
    Chin PKL; Drennan PG; Gardiner SJ; Zhang M; Dalton SC; Chambers ST; Begg EJ
    Br J Clin Pharmacol; 2018 Oct; 84(10):2311-2316. PubMed ID: 29908071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
    Landersdorfer CB; Kirkpatrick CM; Kinzig-Schippers M; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3290-7. PubMed ID: 17576847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations.
    Jager NGL; van Hest RM; Xie J; Wong G; Ulldemolins M; Brüggemann RJM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2020 Sep; 75(9):2641-2649. PubMed ID: 32443147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates.
    Pullen J; de Rozario L; Stolk LM; Degraeuwe PL; van Tiel FH; Zimmermann LJ
    Ther Drug Monit; 2006 Jun; 28(3):351-8. PubMed ID: 16778719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study.
    Meenks SD; Punt N; le Noble JLML; Foudraine NA; Neef K; Janssen PKC
    Crit Care; 2023 Mar; 27(1):82. PubMed ID: 36869388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The simplified oral flucloxacillin absorption test: an accurate method to identify patients with inadequate oral flucloxacillin absorption.
    Dijkmans AC; Kweekel DM; Balmforth C; van Esdonk MJ; van Dissel JT; Burggraaf J; Kamerling IMC
    Neth J Med; 2019 Sep; 77(7):255-260. PubMed ID: 31582580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients.
    Roberts JA; Udy AA; Jarrett P; Wallis SC; Hope WW; Sharma R; Kirkpatrick CM; Kruger PS; Roberts MS; Lipman J
    J Antimicrob Chemother; 2015 May; 70(5):1495-502. PubMed ID: 25608584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis.
    Leder K; Turnidge JD; Korman TM; Grayson ML
    J Antimicrob Chemother; 1999 Jan; 43(1):113-8. PubMed ID: 10381108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients.
    Wallenburg E; Brüggemann RJM; Roberts JA; Jager NGL; Ulldemolins M; Wilkes S; Schouten J; Chin PKL; Ter Heine R
    Clin Microbiol Infect; 2022 Mar; 28(3):446.e1-446.e7. PubMed ID: 34245903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simplified oral flucloxacillin absorption test for patients requiring long-term treatment.
    Dijkmans AC; Hartigh Jd; van Dissel JT; Burggraaf J
    Ther Drug Monit; 2012 Jun; 34(3):356-8. PubMed ID: 22569354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
    Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
    Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
    J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs.
    Moser S; Rehm S; Guertler N; Hinic V; Dräger S; Bassetti S; Rentsch KM; Sendi P; Osthoff M
    J Antimicrob Chemother; 2021 Jun; 76(7):1845-1854. PubMed ID: 33860325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of flucloxacillin during prolonged intermittent renal replacement therapy in a 76-year-old man.
    Fox E; Cheng V; Rawlins M; Dyer J; De Keulenaer B; Page MM; Hoad K; Roberts JA
    J Chemother; 2019; 31(7-8):419-423. PubMed ID: 31650900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low flucloxacillin concentrations in a patient with central nervous system infection: the need for plasma and cerebrospinal fluid drug monitoring in the ICU.
    Abdul-Aziz MH; McDonald C; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Ann Pharmacother; 2014 Oct; 48(10):1380-4. PubMed ID: 24951308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.